Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Novartis investigators went head-to-head with Regeneron’s blockbuster Eylea in two large Phase III studies. And they scored, scooping up promising top-line results and setting up a 2018 filing that puts them on a collision course with the big biotech.
The pharma giant announced this morning that it had hit the primary — non-inferiority to Eylea — and secondary endpoints with RTH258 among 1,800 patients with neovascular age-related macular degeneration (nAMD) across 400 centers worldwide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.